Articles On Orthocell (ASX:OCC)

Title Source Codes Date
Closing Bell: ASX buried under -1.3pc as iron ore miners and goldies take a beating

Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese EV stocks fell ahead of expected EU tariff hikes   Aussie shares slipped after the K...

Stockhead OCC 1 week ago
ASX Health Stocks: Orthocell seeks TGA approval; Race Oncology gets FDA nod

Orthocell (ASX:OCC) has taken a significant step forward in its efforts to introduce its SmrtGraft product to the Australian market. The company has submitted an application to the Therapeutic Goods Administration (TGA) seeking approval to...

Stockhead OCC 2 weeks ago
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Stockhead OCC 3 weeks ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead OCC 1 month ago
Regenerative med firm Orthocell reports near 100pc success rate for dental bone repair product Striate

WA regenerative medicine company Orthocell has reported a near 100 per cent success rate for its dental bone repair product during a recent clinical study.

The West OCC 1 month ago
ASX Health Stocks: RAC says combining lead drug bisantrene with decitabine is effective on solid tumours

Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race...

Stockhead OCC 1 month ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead OCC 1 month ago
Market Close: Quarter gained on sluggish ASX

The ASX200 closed around a quarter of a per cent up with Consumer discretionary topping the gains, finishing nearly half a per cent up and Utilities and Industrials both losing around half a per cent. In the green Mineral explorer IGO...

themarketonline.com.au OCC 1 month ago
Orthocell’s Remplir shows 85% success rate in nerve repair study

Regenerative medicine company Orthocell (ASX:OCC) has published encouraging findings from its Remplir nerve regeneration clinical trial, unveiling promising progress in its peripheral nerve repair journey – offering hope for millions of peo...

themarketonline.com.au OCC 1 month ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead OCC 2 months ago
Botanix joins ASX All Ordinaries as fellow biotech Orthocell boosts cash reserves with $3m R&D tax rebate

Perth clinical dermatology company Botanix has been elevated into the All Ordinaries index made up of the top 500 companies listed on the Australian Securities Exchange.

The West OCC 2 months ago
Orthocell completes all nerve repair surgeries in Remplir US market authorisation study

Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study.

BiotechDispatch OCC 2 months ago
Biotech Orthocell on track to further penetrate US market with Remplir following ‘successful’ study

Regenerative medicine company Orthocell says it has successfully completed the first stage of a pivotal US market authorisation study for its nerve repair product, paving the way for global expansion.

The West OCC 2 months ago
ASX Health Stocks: Argenica flies over 15pc after FDA grants Rare Pediatric Disease Designation

Argenica granted US FDA’s Rare Pediatric Disease Designation Orthocell completes Remplir study, targets US$1b+ nerve repair device market LTR Pharma progresses Erectile Dysfunction study   Argenica gets FDA approval Argenica Therapeutics...

Stockhead OCC 3 months ago
Brokers meet Biotech – four Aussie companies driving medtech solutions

Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun. That was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and...

themarketonline.com.au OCC 3 months ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead OCC 3 months ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead OCC 3 months ago
Chris Ellison, Rod Jones and the McCuskers jump into Orthocell

The $3.5m of shares have been taken up by prominent investors Chris Ellison, Rod Jones, Malcolm and Tonya McCusker and Michael Malone, along with the Merchant Biotech Fund.

The West OCC 4 months ago
Closing Bell: Aussie benchmark fails Tuesday pub test. We should all be there now

  Local markets end slightly lower Telco Sector jumps 1.5pc Small Caps led by Way2Vat   The ASX200 has ended a second slumbrous session slightly lower, with a little dribble in the shape of the Star Casino at the corner of its mouth. US M...

Stockhead OCC 4 months ago
Orthocell announces final positive results of cell therapy in 'tennis elbow' study

Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis.

BiotechDispatch OCC 7 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead OCC 7 months ago
Dr Boreham’s Crucible: Investors have been holding their breath for Pharmaxis’ rebirth. Time to exhale?

In drug development there’s a narrow window to get to market and long delays tend to be fatal – and not just for the patients. Ten years ago, Pharmaxis was confident of US Food and Drug Administration approval for its cystic fibrosis treatm...

Stockhead OCC 7 months ago
Famed plastic surgeon Fiona Wood joins WA biotech Orthocell as a non-executive director

Perth-based regenerative medicine company Orthocell has appointed famed plastic surgeon Fiona Wood to its board as a non-executive director.

The West OCC 8 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead OCC 8 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead OCC 8 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead OCC 9 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead OCC 9 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead OCC 9 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead OCC 10 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead OCC 10 months ago
Orthocell’s product sales ‘significantly’ higher than expected

Orthocell’s sales ramped up in three months to June with the Perth-based regenerative medicine company described as testament to the quality of its products and distribution partners.

The West OCC 10 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead OCC 1 year ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead OCC 1 year ago
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Stockhead OCC 1 year ago
Orthocell taps former health sector leader to chair its board of directors

Australian regenerative medicine company Orthocell (ASX:OCC) has appointed John Van Der Wielen as independent non-executive chairman.

BiotechDispatch OCC 1 year ago
Orthocell all smiles with dental biotech manufacturing site at Murdoch

Orthocell has launched a new bio-manufacturing facility in what boss Paul Anderson said represented the successful translation of quality science into a world-class product.

The West OCC 1 year ago
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

Stockhead OCC 1 year ago
Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Stockhead OCC 1 year ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead OCC 1 year ago
TMH Spotlight: Materials lead the pack in early trade

The Australian share market dipped on Tuesday, with the benchmark ASX 200 index down nearly 20 points halfway through the trading day. The materials sector led the pack in early trade — the only sector to edge into the green. Critical...

themarketherald.com.au OCC 1 year ago
ASX Health Stocks: Neuren’s breakthrough Rett Syndrome drug DAYBUE is now officially available in the US

Neuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study   Market darling Neuren Pharma (ASX:NEU) jumped 4% today after announcing that DAYBUE (trofinetide) is now officially available for the trea...

Stockhead OCC 1 year ago
Orthocell (ASX:OCC) launches fresh rat nerve-repair study

Orthocell (OCC) kicks off a ‘comparator’ study as part of its pre-clinical and clinical development program in nerve repair and regeneration OCC will use a rat sciatic nerve injury model to evaluate the safety, mechanism of action and pr...

themarketherald.com.au OCC 1 year ago
Orthocell appoints US-based nerve surgeons to medical advisory board

Labor has announced that if elected it will launch a $38 million expansion of Australia's newborn screening programs in a move that will effectively see the national take over the current 'postcode lottery' for babies.

BiotechDispatch OCC 1 year ago
Orthocell (ASX:OCC) bolsters medical scientific advisory board with US-based nerve surgeons

Orthocell (OCC) appoints internationally-recognised nerve surgeons Professor Christopher Dy and Professor David Brogan to its medical scientific advisory board The company says the appointments will assist with clinical development and U...

themarketherald.com.au OCC 1 year ago
ASX Health Stocks: Woolworths’ subsidiary partners with Telehealth stock Global Health, share price up 5pc

Telehealth specialist Global Health signs partnership deal with Woolworths subsidiary The deal will see Global Health provide virtual access to healthcare practitioners Orthocell hires experts to drive US market entry   Telehealth special...

Stockhead OCC 1 year ago
Orthocell paves way for other WA firms to compete with global industry heavyweights

Orthocell says a $23 million manufacturing deal for its product has put the regenerative medicine company on the radar of global industry heavyweights, paving the way for other WA firms to do the same.

The West OCC 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead OCC 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead OCC 1 year ago
How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Stockhead OCC 1 year ago
ASX Biotech Stocks: Surgeons can now be reimbursed for using Orthocell’s nerve repair device

Surgeons can now be reimbursed for the use of Orthocell’s nerve-reconstruction device SaaS player ReadyTech is considering a takeover offer from an Aussie private equity firm Creso is raising up to $7.6m to advance sales and marketing of i...

Stockhead OCC 1 year ago